Accelerating GBM Drug Development with Innovative Patient-Derived Models of the TME
- Advancing organoids and xenografts for high-throughput screening and biomarker identification to effectively evaluate novel therapeutic strategies and reduce failure risk
- Discussing the maintenance of genetic and molecular heterogeneity of human tumors to provide a more predictive platform for preclinical research
- Modelling recurrent tumors with patient-derived models to replicate selection pressure from prior therapies